论文部分内容阅读
目的评价e抗原阳性的慢性乙型肝炎患者治疗前ALT、HBV DNA水平以及治疗12周时,HBV抑制程度对拉米夫定治疗52周患者疗效评价。方法97例HBeAg阳性成年慢性乙型肝炎患者进入研究,HBV DNA定量≥104拷贝/ml,血清ALT水平1.5～10倍正常上限(ULN)接受拉米夫定0.1g/d共52周治疗,定期随访。检测血清HBV标志物及HBV DNA,比较不同基线ALT,HBV DNA水平及治疗12周时HB VDNA水平患者,治疗52周时的疗效差异。结果治疗52周时血清HBV DNA水平与HBeAg血清转换与治疗12周时血清HBV DNA相关(P<0.01)。结论HBeAg阳性慢性乙型肝炎患者,拉米夫定治疗12周时血清HBV DNA水平对治疗52周的疗效:治疗12周时HBV DNA<103拷贝/ml,52周时疗效更佳。
Objective To evaluate the therapeutic effect of HBV pretreatment on serum ALT, HBV DNA level and the degree of HBV suppression in patients with chronic hepatitis B e antigen positive 52 weeks after 52 weeks of lamivudine treatment. Methods Ninety-seven patients with HBeAg-positive adult chronic hepatitis B were enrolled in the study. The HBV DNA quantitation was ≥104 copies / ml, the serum ALT level was 1.5-10 times upper limit of normal (ULN), and lamivudine 0.1g / d was given for 52 weeks. Follow-up. Serum HBV markers and HBV DNA were detected. The difference in efficacy between different baseline ALT, HBV DNA levels and HBVDNA levels at 12 weeks was compared. Results Serum HBV DNA levels at 52 weeks of treatment were correlated with serum HBV DNA levels after HBeAg seroconversion and 12 weeks of treatment (P <0.01). Conclusions In patients with HBeAg-positive chronic hepatitis B, the effect of serum HBV DNA level after 52 weeks of lamivudine therapy on 52 weeks of treatment is as follows: HBV DNA <103 copies / ml at 12 weeks of treatment have a better effect at 52 weeks.